

Clinical Policy: Tandem Transplant

Reference Number: LA.CP.MP.162

Date of Last Revision: 3/26

[Coding Implications](#)

[Revision Log](#)

[See Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

A tandem transplant, also known as a sequential or double transplant, refers to a planned second course of high-dose therapy and hematopoietic cell transplant (HCT) within six months of the first course.¹ It differs from a repeat HCT, as it is planned prospectively rather than performed due to relapse. Tandem transplants are performed to obtain greater and extended response rates. This policy describes the medical necessity requirements for these transplants.

Policy/Criteria

- I. It is the policy of Louisiana Healthcare Connections that a *tandem autologous transplant* is **medically necessary** when meeting all the following criteria:
 - A. Member/enrollee has any of the following diagnoses:
 1. Newly diagnosed or responsive multiple myeloma (MM);
 2. Germ cell tumors that are refractory to cisplatin-based chemotherapy, including one of the following:
 - a. Relapsed testicular germ cell tumors;
 - b. Relapsed ovarian germ cell tumors;
 3. High-risk neuroblastoma in a member/enrollee < 18 years of age characterized by any of the following:
 - a. Stage M, aged ≥ 18 months, regardless of other features;
 - b. Stage M, aged < 18 months with MYCN-amplified disease;
 - c. Stage MS or L2 with MYCN-amplified disease;
 - d. Stage L2 with unfavorable histology, aged ≥ 18 months;
 - e. Stage M or MS, aged 12 to 18 months with at least one of the following unfavorable features:
 - i. Unfavorable histology;
 - ii. Segmental chromosomal aberrations;
 - iii. Diploid tumor;
 - f. Stage L1 incompletely resected tumor with MYCN amplification;
 - B. Does not have significant dysfunction of a major organ system and/or severe comorbidities, including, but not limited to, any of the following:
 1. Bilirubin > 2 mg/dL;
 2. Hemostasis: international normalized ratio (INR) > 1.6 (unless on oral anticoagulants);
 3. Cardiac function: multigated acquisition (MUGA) scan or echocardiogram with ejection fraction (EF) < 45%;
 4. Pulmonary function, one of the following:
 - a. Forced expiratory volume in 1 second (FEV1) $\leq 50\%$ of predicted value;
 - b. Diffusing capacity of the lung for carbon monoxide (DLCO) $\leq 60\%$ of predicted value;
 5. Performance scale index, one of the following:
 - a. Karnofsky or Lansky score < 70%;

- b. Eastern Cooperative Oncology Group (ECOG) performance score > 2.
- 6. Uncontrolled or disseminated infection.

II. It is the policy of Louisiana Healthcare Connections that a *tandem autologous transplant followed by an allogeneic transplant* from a human leukocyte antigen (HLA)-identical sibling donor with reduced-intensity conditioning is **medically necessary** for untreated, newly diagnosed MM, when none of the contraindications in section I.B. are present.

III. It is the policy of Louisiana Healthcare Connections that a *tandem autologous transplant followed by an allogeneic transplant* from an HLA-compatible unrelated donor for untreated, newly diagnosed MM, and with none of the contraindications in section I.B., will be considered on a case-by-case basis.

Background

During a tandem transplant, peripheral blood hematopoietic stem cells (HSCs) are collected either during recovery of a cycle of induction chemotherapy or after filgrastim mobilization. The patient receives a second preparative regimen, along with hematopoietic progenitor cells (HPCs) collected during the initial mobilization.¹⁰ The rationale for the second round of therapy is to destroy any residual tumor cells remaining after the initial transplant and thereby reduce the chance of relapse.

Multiple Myeloma

Multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. MM is a disease of older adults and is classified as either smoldering myeloma (asymptomatic) or MM (symptomatic). Individuals with smoldering disease have no related organ or tissue impairment. All patients with smoldering myeloma have a risk of progression to MM. However, the rate of progression varies from months to several years based on certain risk factors. The historic approach for management of smoldering myeloma has been close observation. However, recently there has been mounting evidence that those with high-risk features may benefit for early intervention.¹ Individuals with symptomatic MM are initially treated with primary therapy, and primary therapy is followed by high-dose chemotherapy with autologous HCT in transplant-eligible patients. Although responses are typically durable, relapse is an expected part of the disease course, and MM is not considered curable with current approaches.¹

Following diagnosis and risk stratification, all patients need assessment to determine eligibility for HCT. National Comprehensive Care Network (NCCN) guidelines indicate that all types of HCT are appropriate in different clinical settings (i.e., single autologous HCT, a tandem HCT, or an allogeneic HCT). Allogeneic HCT should preferentially be done in the context of a trial when possible. Autologous HCT results in high response rates and remains standard of care after primary therapy for eligible patients.¹ However, some controversy currently exists in the era of newer and more effective chemotherapy agents. Eligibility varies across countries and institutions. NCCN guidelines recommend autologous HCT for transplant-eligible patients as an option after primary induction therapy, while a delayed HCT after early stem cell collection and storage is appropriate as well (category 1). A repeat HCT can be considered for treatment of progressive/refractory disease after primary treatment in patients with prolonged response to initial HCT.

Planned tandem transplants have been studied in several randomized trials. Results of a phase III trial (StaMINA) indicate that a tandem autologous stem cell transplant (SCT) followed by lenalidomide maintenance has similar outcomes to a single autologous SCT followed by lenalidomide maintenance in the initial treatment of MM. However, another multicenter phase III trial suggests that tandem autologous SCT for newly diagnosed MM appears to be superior in extending progression free survival (PFS) compared with a single SCT after induction therapy with a bortezomib-based regimen.⁷ A conventional meta-analysis and network meta-analysis of phase three RCTs comparing high dose therapy (HDT)/autologous SCT with standard-dose therapy (SDT) using novel agents showed that both tandem HDT/autologous SCT and single HDT/autologous SCT with bortezomib, lenalidomide, and dexamethasone were superior to single HDT/autologous SCT alone and SDT for PFS, but overall survival was similar across the four approaches.¹¹

The NCCN Multiple Myeloma panel recommends collecting enough hematopoietic stem cells for two transplants in all eligible patients (depending on the intended number of transplants and age). According to the panel, a tandem transplant with or without maintenance therapy can be considered for all patients who are candidates for HCT and is an option for patients who do not achieve at least a very good partial response (VGPR) after the first autologous HCT and those with high-risk features.¹

Neuroblastoma

Neuroblastoma is the most common extracranial solid tumor in childhood with more than 650 cases diagnosed each year in North America. Approximately 90% of those diagnosed with neuroblastoma are younger than five years of age. The data on age at diagnosis show that this is a disease of infancy, with the highest rate of diagnosis in the first month of life.¹⁷ Neuroblastomas vary in terms of location, histopathologic appearance, and biologic characteristic and can occur anywhere along the sympathetic chains, however, the adrenal gland is the most common primary site followed by abdominal, thoracic, cervical and pelvic sympathetic ganglia. The presenting symptoms reflect the location of the primary tumor and the extent of metastatic disease, if present. Patients with localized disease can be asymptomatic, whereas children with advanced disease appear ill at presentation, usually with systemic symptoms.¹³

Age, stage, and biological features encountered in tumor cells are important prognostic factors and are used for risk stratification and treatment assignment. Currently, the most commonly used system for neuroblastoma staging is the International Neuroblastoma Risk Group Staging System (INRGSS), which uses results from imaging tests (such as CT or MRI and MIBG scan) prior to surgery to help decide a stage. The INRGSS can be determined before treatment has started and divides neuroblastomas into four stages. Knowledge regarding the presence or absence of image defined risk factors (IDRF) are required for this staging system. Additionally, the Children's Oncology Group (COG) neuroblastoma risk classification is a system used to group neuroblastoma tumors into three risk groups: low risk, intermediate risk, or high risk.¹⁵ Risk group assignment incorporates patient age, disease stage at diagnosis, MYCN amplification status, tumor histology, and tumor-specific genetic changes.¹⁵

International Neuroblastoma Risk Group Staging System (INRGSS)¹⁵

Stage	Description
L1	Localized tumor not involving vital structures as defined by the list of image-defined risk factors and confined to one body compartment
L2	Locoregional tumor with presence of one or more image-defined risk factors
M	Distant metastatic disease (except stage MS)
MS	Metastatic disease in children younger than 18 months with metastases confined to skin, liver, and/or bone marrow

Children's Oncology Group (COG) Neuroblastoma Risk Grouping High-Risk Disease¹⁵

High-Risk Disease
Stage M, aged \geq 18 months, regardless of other features
Stage M, aged $<$ 18 months with MYCN-amplified disease
Stage MS or L2 with MYCN-amplified disease
Stage L2 with unfavorable histology, aged \geq 18 months
Stage M or MS 12 to 18 months with at least one unfavorable feature: <ul style="list-style-type: none"> • Unfavorable histology • Segmental chromosomal aberrations • Diploid tumor
Stage L1 incompletely resected tumor with MYCN amplification

Treatment of neuroblastoma is determined based on risk categories. Risk categories are expected to evolve as newer staging systems are adopted and further knowledge is acquired about molecular and genetic determinants of tumor behavior and prognosis.¹³ Patients are classified into low, intermediate, and high-risk categories based on the following characteristics at the time of diagnosis:

- Stage of the disease
- Patient age
- Extent of INRGSS L1 disease resection
- Presence or absence of amplification of the MYCN oncogene
- Quantitative DNA content of the tumor (DNA index or ploidy).
- Histologic appearance of the tumor
- Segmental chromosomal aberrations (eg, loss of heterozygosity)

Patients with low-risk and intermediate-risk neuroblastoma have excellent prognosis and outcome. However, those with high-risk disease continue to have very poor outcomes despite intensive therapy. Patients at the highest risk for disease progression and mortality are those who are older than 18 months of age and have disseminated disease, or localized disease with unfavorable markers such as MYCN amplification (high-risk neuroblastoma).¹³

Historically, the long-term survival probability for children with high-risk disease was less than 15 percent. Better results have been achieved using an aggressive multimodality approach that includes chemotherapy, surgical resection, high-dose chemotherapy with hematopoietic stem-cell rescue, and radiation therapy. Results from randomized trials have consistently demonstrated improved progression-free survival in patients who received myeloablative chemotherapy with stem cell rescue, and some of these studies demonstrated an improvement in overall survival in certain groups of patients.¹³

Two sequential cycles of myeloablative chemotherapy and stem cell rescue given in a tandem fashion has been shown to be feasible for patients with high-risk neuroblastoma.¹⁷ A recent multicenter RCT comparing tandem vs. single consolidation in patients with high risk neuroblastoma reported that in

children with high-risk neuroblastoma, tandem autologous stem cell transplant (ASCT) improved event-free survival rates. While the tandem transplant group experienced improved three-year event-free survival (EFS) compared with those receiving single transplants (61 versus 48 percent), the difference in overall survival at three years did not reach statistical significance (74 versus 69 percent). For the subset of patients receiving immunotherapy, tandem transplants were associated with improvements in both EFS (74 versus 56 percent) and overall survival (84 versus 76 percent). Cumulative rates of severe mucosal, infectious, or liver toxicities and regimen-related mortality were similar between arms.¹⁸

Testicular Cancer

Testicular cancer is the most common solid malignancy affecting those with a male reproductive system between the ages of 20 and 34. Germ cell tumors (GCTs) account for 95 percent of testicular cancers.²³ Testicular cancers are among the most curable solid neoplasms with the current five-year survival rate at over 95 percent. Initial therapy of early stage testicular GCTs is based upon histology and tumor extent.²⁵ NCCN guidelines recommend radical inguinal orchiectomy as the primary treatment for most patients with a testicular mass that is concerning for malignancy on ultrasound. Additionally, platinum-based combination chemotherapy can cure patients with disseminated GCTs, even in the context of widespread visceral metastases, highly elevated serum tumor markers, and other adverse prognostic features.

Those with GCTs in second or subsequent relapse, and those who progress during or immediately after their initial platinum-based chemotherapy regimen are considered to have platinum- refractory disease. These patients have a poorer prognosis than those treated with chemotherapy for their initial relapse.²⁶ Those who are diagnosed with relapsed or refractory testicular GCTs should be referred to a cancer center with multidisciplinary expertise, and patients should be offered the opportunity to participate in clinical studies whenever possible.²⁵ High-dose chemotherapy followed by autologous stem cell transplant, either single or tandem, is an accepted treatment option for these patients. An observational study that compared results of patients intended to undergo tandem autotransplant versus those in whom a second autotransplant was not planned, reported that tandem autotransplants are associated with less treatment-related mortality than a planned single transplant, with no differences in disease-related outcomes or overall survival at three years.²⁶ It is important to note that a significant percent of patients undergoing planned tandem HSCT in this study had poorer risk features including more advanced disease at diagnosis and greater likelihood of exhibiting cisplatin resistance when compared to subjects where two autotransplants were not planned.

Coding Implications

This clinical policy references Current Procedural Terminology (CPT[®]). CPT[®] is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2025, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only and may not support medical necessity. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

NOTE: Coverage is subject to each requested code's inclusion on the corresponding LDH fee schedule. Non-covered codes are denoted (*) and are reviewed for Medical Necessity for members under 21 years of age on a per case basis.

CPT Codes	Description
38205	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic
38206	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous
38230	Bone marrow harvesting for transplantation; allogeneic
38232	Bone marrow harvesting for transplantation; autologous
38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor
38241	Hematopoietic progenitor cell (HPC); autologous transplantation

HCPCS Codes	Description
S2150*	Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre and post-transplant care in the global definition

Reviews, Revisions, and Approvals	Revision Date	Approval Date	Effective Date
Converted corporate to local policy.	08/15/20		
Added “may not support medical necessity” to coding implications. Replaced contraindications regarding past or current nonadherence to medical therapy, and psychological condition associated with the inability to comply with medical therapy with “Inability to adhere to the regimen necessary to preserve the transplant, even with caregiver support.”	2/22	2/22	
Replaced contraindications “Inadequate cardiac, renal, pulmonary, or hepatic function and significant, uncorrectable, life-limiting medical condition” with those concerning GFR, acute liver failure..., acute renal failure..., septic shock, active extrapulmonary or disseminated infection, active tuberculosis infection, HIV infection with detectable viral load, progressive cognitive impairment, other severe uncontrolled medical condition... Updated references. Added and may not support medical necessity to Coding Implications section	5/22	8/13/22	
Updated verbiage I.3.b.ii., I.3.c.i. through iii., and I.A.3.d. Added substance use contraindication I.B.15. Removed criteria IV. stating, current evidence does not support tandem transplants for any other indication than what is listed above. Added CPT code 38243. Updated references.	4/23	7/21/23	
Annual review. Added a. through c. to I.B.10.; a. CD4 cell count > 200 cells/mm ³ , b. Absence of active AIDS-defining opportunistic infection, and c. Member/enrollee is currently on effective ART (antiretroviral therapy). Updated background info on testicular cancer with no impact on criteria. References reviewed and updated.	3/24	5/22/24	6/21/24

Reviews, Revisions, and Approvals	Revision Date	Approval Date	Effective Date
Annual review. Updated I.A.3.b., c. and d. to reflect months of age instead of days. Replaced all previous contraindications, I.B.1. through 15. with new contraindication list, I.B.1. through 6. Background updated with no impact on criteria. References reviewed and updated. Reviewed by external specialist.	03/25	5/20/25	6/19/25
Annual review. Updated Criteria I.A.2. to include ovarian germ cell tumors. Updated Criteria I.A.3. from neuroblastoma characteristics from the International Neuroblastoma Staging System (INSS) to characteristics from the International Neuroblastoma Risk Group Staging System (INRGSS) and Children's Oncology Group (COG) neuroblastoma high-risk disease group. Background updated with to reflect information regarding INRGSS. Coding and descriptions reviewed. References reviewed and updated. Reviewed by internal specialist and external specialist.	03/26	5/27/26	6/26/26

References

1. National Comprehensive Care Network. NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 3.2026. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Published November 03, 2025. Accessed November 21, 2025.
2. Shah N, Callander N, Ganguly S, et al. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2015;21(7):1155-1166. doi:10.1016/j.bbmt.2015.03.002
3. Giralt S, Garderet L, Durie B, et al. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. *Biol Blood Marrow Transplant*. 2015;21(12):2039 through 2051. doi: 10.1016/j.bbmt.2015.09.016
4. Laubach JP. Multiple myeloma: Overview of management. UpToDate. www.uptodate.com. Updated September 24, 2025. Accessed October 28, 2025.
5. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2015;21(11):1863 through 1869. doi:10.1016/j.bbmt.2015.07.032
6. Holmberg LA, Deeg HJ, Sandmaier BM. Determining eligibility for autologous hematopoietic cell transplantation. UpToDate. www.uptodate.com. Updated November 14, 2024. Accessed October 30, 2025.
7. Barlogie B, Attal M, Crowley J, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. [published correction appears in *J Clin Oncol*. 2010 Jul 20;28(21):3543]. *J Clin Oncol*. 2010;28(7):1209 through 2014. doi:10.1200/JCO.2009.25.6081
8. Kumar S. Multiple myeloma: Use of hematopoietic cell transplantation. UpToDate. www.uptodate.com. Updated September 11, 2025. Accessed October 31, 2025.
9. LeMaistre CF, Farnia S, Crawford S, et al. Standardization for terminology of episodes of hematopoietic stem cell patient transplant care. *Biol Blood Marrow Transplant*. 2013; 19(6):851 through 857. doi:10.1016/j.bbmt.2013.03.004
10. Dhakal B, Szabo A, Chhabra S. et al. Autologous Transplantation for Newly Diagnosed Multiple

- Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. *JAMA Oncol.* 2018;4(3):343-350. doi:10.1001/jamaoncol.2017.4600
11. Yin X, Tang L, Fan F, Jiang Q, Sun C, Hu Y. Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017. *Cancer Cell Int.* 2018;18:62. doi:10.1186/s12935-018-0553-8
 12. Garderet L, Beohou E, Caillot D, et al. Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. *Haematologica.* 2016;101(11):1390 through 1397. doi:10.3324/haematol.2016.150334
 13. Shohet JM, Nuchtern JG, Foster JH. Treatment and prognosis of neuroblastoma. UpToDate. www.uptodate.com. Updated October 15, 2025. Accessed November 04, 2025.
 14. Björkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. *J Clin Oncol.* 2011;29(22):3016 through 3022. doi:10.1200/JCO.2010.32.7312
 15. National Cancer Institute. Neuroblastoma treatment (PDQ®) – Health professional version. <https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq>. Updated April 28, 2025. Accessed November 14, 2025.
 16. Htut M, D'Souza A, Krishnan A, et al. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. *Biol Blood Marrow Transplant.* 2018;24(3):478 through 485. doi:10.1016/j.bbmt.2017.10.024
 17. Seif AE, Naranjo A, Baker DL, et al. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. *Bone Marrow Transplant.* 2013;48(7):947 through 952. doi:10.1038/bmt.2012.276
 18. Park JR, Kreissman SG, London WB, et al. A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study. *J Clin Oncol.* 2016;34(18).
 19. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. *J Clin Oncol.* 2006;24(18):2891 through 2896. doi:10.1200/JCO.2006.05.6986
 20. Granger M, Grupp SA, Kletzel M, et al. Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: a Pediatric Oncology Group study: a report from the Children's Oncology Group. *Pediatr Blood Cancer.* 2012;59(5):902 through 907. doi:10.1002/pbc.24207
 21. Qayed M, Chiang KY, Ricketts R, et al. Tandem stem cell rescue as consolidation therapy for high-risk neuroblastoma. *Pediatr Blood Cancer.* 2012;58(3):448 through 452. doi:10.1002/pbc.23155
 22. Sung KW, Ahn HS, Cho B, et al. Efficacy of tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma: the Korean Society of Pediatric Hematology-Oncology experience over 6 years (2000 through 2005). *J Korean Med Sci.* 2010;25(5):691 through 697. doi:10.3346/jkms.2010.25.5.691
 23. National Comprehensive Care Network®. NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. Version 1.2026. https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf Published October 15, 2025. Accessed November 24, 2025.
 24. Steele GS, Richie JP, Michaelson MD. Clinical presentation, diagnosis, and staging of testicular germ cell tumors. UpToDate. www.uptodate.com. Updated August 27, 2025. Accessed November 21, 2025.
 25. Gilligan TD, Tyson M. Diagnosis and treatment of relapsed and refractory testicular germ cell tumors. UpToDate. www.uptodate.com. Updated March 06, 2025. Accessed November 24, 2025.

26. Lazarus HM, Stiff PJ, Carreras J, et al. Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysis. *Biol Blood Marrow Transplant*. 2007;13(7):778 through 789. doi:10.1016/j.bbmt.2007.02.013
27. Necchi A, Miceli R, Pedrazzoli P, et al. Predictors of CD34+ cell mobilization and collection in adult men with germ cell tumors: implications for the salvage treatment strategy. *Clin Genitourin Cancer*. 2014;12(3):196-202.e1. doi:10.1016/j.clgc.2013.11.021
28. Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. *J Clin Oncol*. 2019;37(7):589 through 597. doi: 10.1200/JCO.18.00685
29. Park JR, Kreissman SG, London WB, et al. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. *JAMA*. 2019;322(8):746 through 755. doi:10.1001/jama.2019.11642
30. Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant*. 2021;40(11):1349 through 1379. doi:10.1016/j.healun.2021.07.005
31. Agüero F, Castel MA, Cocchi S, et al. An Update on Heart Transplantation in Human Immunodeficiency Virus-Infected Patients. *Am J Transplant*. 2016;16(1):21 through 28. doi:10.1111/ajt.13496
32. Davidoff AM. Neuroblastoma. *Semin Pediatr Surg*. 2012;21(1):2-14. doi:10.1053/j.sempedsurg.2011.10.009
33. National Comprehensive Care Network®. NCCN Clinical Practice Guidelines in Oncology: Neuroblastoma. Version 1.2025. https://www.nccn.org/professionals/physician_gls/pdf/neuroblastoma.pdf. Published April 16, 2025. Accessed November 25, 2025.
34. Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. *J Clin Oncol*. 2007;25(5):513-516. doi:10.1200/JCO.2006.07.7271

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this

clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

©2023 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.